The liver is a common metastatic organ for end-stage malignant tumors, and the gastrointestinal tract is the most common primary site. For patients with colorectal cancer, when the tumor metastasizes to distant sites, 18.0% to 83.0% of patients will have liver metastasis, among which 20.0% to 40.0% of liver metastases are found at the same time with the primary tumor of colorectal cancer. The incidence of liver metastases from gastric cancer is as high as 40.0% to 50.0%, and they are often accompanied by extrahepatic metastases, peritoneal dissemination and direct invasion of surrounding organs. Even after radical surgery, about 50.0% of patients with early gastric cancer still fail treatment due to various recurrences and metastases after surgery, of which liver metastases account for 5.0% to 29.0%. Liver metastasis of gastric cancer accounts for about 38.1% of organ metastasis of gastric cancer, ranking first among organ metastasis of gastric cancer. It can be seen that liver metastasis is the biggest killer of gastrointestinal cancer patients and the most important factor affecting their prognosis. The severe form forces people to constantly seek and explore new effective treatment methods for metastatic liver cancer. At present, surgical treatment, chemotherapy, catheterization and radiofrequency ablation play important roles in the treatment arena of metastatic liver cancer, respectively, and their treatment concepts and strategies are constantly updated and developed with the emergence of a large amount of evidence-based medical evidence. Surgical treatment is an effective means of possible cure for resectable metastatic liver cancer. 15.0%-25.0% for concurrent liver metastases and 22.0%-50.0% for heterochronic liver metastases. For colorectal cancer liver metastases, surgical resection is recognized as the only possible curative treatment for colorectal cancer liver metastases. According to the literature, the survival rates at 5, 10 and 20 years after surgery for colorectal cancer liver metastases are 37.0%, 28.0% and 24.0%, respectively, while the median survival of untreated patients is less than 12 months. Surgical resection of the primary site is recommended as the standard of care for patients with progressive gastric cancer, but the value of surgical treatment for patients with liver metastases from gastric cancer is inconclusive. Surgery for liver metastases from colorectal cancer is considered to be the only possible treatment to cure the disease, with a 5-year survival rate of 30.0% to 50.0%, but liver metastases from gastric cancer are often multifocal across lobes or even diffusely disseminated, and often combined with peritoneal metastases, extensive lymph node metastases and distant organ metastases. The 5-year survival rate after liver resection for gastric cancer metastases is only 10.0%-20.0%, with a median survival time of 12-34 months, and only about 10.0% of patients are suitable for liver resection. Currently, the indications for surgical treatment of liver metastases from gastric cancer and the timing of surgery have become hot spots for surgeons to study and discuss. Systemic chemotherapy is the main method to prolong the survival of unresectable metastatic liver cancer patients. Systemic chemotherapy is the main treatment for unresectable metastatic liver cancer, which can also shrink and reduce the stage of liver metastases and create conditions for surgical resection. For most unresectable liver metastases, systemic chemotherapy becomes the main treatment method to control tumor progression. Currently, the effective chemotherapeutic drugs for colorectal cancer with liver metastases include: 5-fluorouracil (5-FU), platinum oxalate, and topoisomerase (CPT-11) drugs, and the combination is better than monotherapy. Systemic chemotherapy is also considered as one of the main treatments for metastatic gastric cancer, and chemotherapy can extend the median survival of metastatic gastric cancer from 3 to 5 months to 8 to 12 months, reflecting a certain therapeutic value, but the choice of treatment regimen is not as standardized as that for colorectal cancer, and it is controversial what is the standard treatment regimen. The emergence of many new drugs (such as third-generation platinum derivatives platinum oxalate, paclitaxel, topoisomerase I inhibitors camptothecin, gemcitabine, pemetrexed, S1) has made chemotherapy for advanced gastric cancer more effective and safe. Molecular targeted therapy provides a highly effective and low-toxic treatment for metastatic liver cancer Molecular targeted therapy targets certain signature molecules overexpressed by tumor cells and selects targeted blocking agents to inhibit tumor growth, progression and metastasis. With molecular specificity and selectivity, this therapy can efficiently and selectively kill tumor cells and reduce damage to human normal tissues, which is a new direction in the development of tumor therapy. At present, the molecular targeted drugs with clear effects on gastrointestinal metastatic liver cancer include: cetuximab (EGFR), bevacizumab (VEGFR) and trastuzumab. Radiofrequency ablation is a powerful supplement to the surgical treatment of metastatic liver cancer. Radiofrequency ablation has been considered as one of the common treatments for primary solid tumors or metastatic tumors. In the treatment of patients with colorectal liver metastases, radiofrequency ablation is mainly used for patients who cannot be surgically resected. Early studies reported that the complete response rate of liver metastases to radiofrequency ablation did not exceed 60.0%-70.0%. However, with the improvement of radiofrequency ablation technology, the success rate of radiofrequency ablation in the treatment of liver metastases has gradually increased. The comparison of the efficacy of radiofrequency ablation and surgical resection of liver metastases is one of the concerns. Portal vein thrombosis (PVE) is to embolize and atrophy the liver lobe containing the tumor and promote the growth of the opposite liver lobe, so that patients with liver metastases that cannot be directly resected by surgery can have the opportunity to be resected by surgery, thus expanding the indication for surgery. Portal vein embolization can result in 20.0% to 50.0% of remaining lobe hyperplasia, allowing 60.0% to 82.0% of patients with liver metastases to undergo surgery after PVE, with a 5-year survival rate of 25.0% to 50.0%. Although PVE has enabled more patients with liver metastases from colorectal cancer to be surgically resected, studies have also reported that PVE can also promote tumor growth, thereby decreasing long-term survival. Therefore, patients with PVE need to be strictly screened and moderately selected, and PVE must be avoided for those whose residual liver is expected to be able to meet the compensatory function of the liver. Hepatic artery catheter embolization is an optional treatment for unresectable metastatic hepatocellular carcinoma Hepatic artery chemoembolization (TACE) is one of the common methods for unresectable hepatic metastatic carcinoma. A phase II clinical study by Arai et al. showed that the combination of transhepatic arterial catheter 5-FU, adriamycin and mitomycin for liver metastases from gastric cancer also showed a high response rate of 73.0% (22/30). Patients often die due to extrahepatic metastases, and hepatic artery catheter chemotherapy does not really achieve the goal of improving survival. Metastatic hepatocellular carcinoma is the end stage of malignancy and is the main cause of death. Various treatment strategies are being attempted to prolong patient survival by eradicating metastatic liver cancer or controlling its progression. However, with the emergence of new effective chemotherapeutic drugs and chemotherapy regimens, the expansion of indications for liver metastatic cancer surgery, the emergence of new adjuvant therapies, the intervention of integrated treatment concepts from multiple disciplines and the evidence-based treatment from large-scale multicenter clinical trials, the treatment of metastatic liver cancer is still in the exploratory stage.